TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22855332

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice a day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20532723

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 3 mg/kg/hr infusion)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 18782527

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16255352

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement containing 2.5% chlorhexidine (GI-CHX)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Glass ionomer (GI)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 262
Study: 12492906

Group type: EXPERIMENTAL
Intervention: 15 mg CHX 2 x daily for 30 s (0.1% CHX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9 mg CHX 2 x daily for 60 s (0.06% CHX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 ml SFAF rinse 1 x daily for 30 s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg CHX 2 x daily for 30 s (0.06% CHX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15 ml placebo 2 x daily for 60 s
Number of subjects: 20
Study: 10030791

Group type: EXPERIMENTAL
Intervention: Postinjury PMNs stimulated with LPS (100 ng)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Elective surgical patients (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postinjury PMNs
Number of subjects: 12
Study: 8525690

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 2, and 6 months of age
Number of subjects: 626

Group type: COMPARATOR
Intervention: DTP and oral polio vaccines
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 626

Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 626

Group type: COMPARATOR
Intervention: Polio vaccine
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine with DTP and polio vaccines
Number of subjects: 626
Study: 2359570

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg three times daily during menses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Norethisterone (5 mg twice daily on days 19-26 of the cycle)
Number of subjects: 72
Study: 1119429

Group type: EXPERIMENTAL
Intervention: Egg albumen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amino acid mixture (essential and nonessential)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Essential amino acids plus nonspecific nitrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet with egg albumen
Number of subjects: 0
Study: 31764564

Group type: EXPERIMENTAL
Intervention: Endoscope-Assisted Coblation Adenoidectomy (EACA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Curettage Adenoidectomy (CCA)
Number of subjects: 72
Study: 30854750

Group type: EXPERIMENTAL
Intervention: Modified one-handed chest compression (OHCC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional one-handed chest compression (OHCC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both modified and conventional OHCC
Number of subjects: 46
Study: 27486204

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 250 mg daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26527788

Group type: EXPERIMENTAL
Intervention: Colonoscopy at 3 years and 6 years (group B)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Colonoscopy at 6 years (group A)
Number of subjects: 528
Study: 24163386

Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Bupropion plus escitalopram
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Venlafaxine plus mirtazapine
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 662
Study: 21525260

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols beverage providing 1402 mg total catechins/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols beverage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (0.5, 1.0, and 2.0 g) in a separate study
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 60
Study: 19448047

Group type: EXPERIMENTAL
Intervention: Telephone Audio Computer‐Assisted Self‐Interviewing (T‐ACASI)
Number of subjects: 2287
Study: 16537867

Group type: EXPERIMENTAL
Intervention: Heliox inhalation for 1 hour
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airox inhalation for 1 hour
Number of subjects: 20
Study: 12751807

Group type: EXPERIMENTAL
Intervention: Task A easy with Task B difficult
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task A easy with Task B easy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task A difficult with Task B easy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task A difficult with Task B difficult
Number of subjects: 0
Study: 10831074

Group type: EXPERIMENTAL
Intervention: i.v. mycophenolate mofetil (MMF) 1 g Q12h
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (used in the safety study only, 2:1 MMF:placebo)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: i.v. mycophenolate mofetil (MMF) 1 g b.i.d.
Number of subjects: 198
Study: 9085956

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (3 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% lidocaine (1.5 mg/kg) with 1 microg/kg of fentanyl and 0.5 mg of pancuronium
Number of subjects: 40
Study: 8462137

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 3028660

Group type: EXPERIMENTAL
Intervention: Ifosfamide administered with mesna (IFO/M)
Number of subjects: 0
Study: 30144512

Group type: COMPARATOR
Intervention: Weight gain subgroup (n=43)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Stable weight subgroup (n=260)
Number of subjects: 347
Study: 27088583

Group type: EXPERIMENTAL
Intervention: PCV‐13 booster
Number of subjects: 178

Group type: COMPARATOR
Intervention: PCV‐10 booster
Number of subjects: 178
Study: 25055491

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐0.7 microg/kg per hour)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Propofol (0.3‐2 mg/kg per hour)
Number of subjects: 55
Study: 22079736

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy combined with long-term androgen deprivation therapy
Number of subjects: 97
Study: 20535924

Group type: EXPERIMENTAL
Intervention: Periodontal initial therapy together with Chinese herbal compound (TCM) for clearing heat and detoxification
Number of subjects: 24

Group type: COMPARATOR
Intervention: Periodontal initial therapy alone (Control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 24
Study: 17214996

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg (C600)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg (C300)
Number of subjects: 58
Study: 15947771

Group type: EXPERIMENTAL
Intervention: Doppler tissue velocities (DTV)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control subjects (age-matched)
Number of subjects: 31
Study: 11819153

Group type: EXPERIMENTAL
Intervention: Idebenone 360 mg/day
Number of subjects: 203

Group type: COMPARATOR
Intervention: Tacrine up to 160 mg/day
Number of subjects: 203
Study: 10566611

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin with newer agents (vinorelbine or paclitaxel)
Number of subjects: 0
Study: 8948920

Group type: EXPERIMENTAL
Intervention: Dinoprostone 0.5 mg in gel form (intracervically applied)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without PGE2 application)
Number of subjects: 0
Study: 2021987

Group type: EXPERIMENTAL
Intervention: midazolam 0.08 mg.kg‐1
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg.kg‐1 with perphenazine 2.5‐5.0 mg im
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 85
Study: 7021431

Group type: EXPERIMENTAL
Intervention: Propiram 50 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propiram 100 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31347920

Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy (6 standardized 35-min weekly sessions)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional therapeutic exercises (CTEs) (6 standardized 35-min weekly sessions)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional therapeutic exercises (CTEs)
Number of subjects: 70
Study: 28406814

Group type: EXPERIMENTAL
Intervention: Cooling to 34‐36°C for 48 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Historical controls (not cooled)
Number of subjects: 66
Study: 26004968

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 56
Study: 23192725

Group type: EXPERIMENTAL
Intervention: Midazolam continuous infusion in hypothermic patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Midazolam as sedative in control group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetics between groups
Number of subjects: 17
Study: 22042783

Group type: EXPERIMENTAL
Intervention: FAC + G-CSF (5-FU 600 mg/m², doxorubicin 60 mg/m², cyclophosphamide 1000 mg/m² every 18 days for four cycles)
Number of subjects: 202

Group type: COMPARATOR
Intervention: FAC (5-FU 500 mg/m², doxorubicin 50 mg/m², cyclophosphamide 500 mg/m² every 21 days for four cycles)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FAC + G-CSF
Number of subjects: 202

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 202
Study: 18789432

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS: 5.8%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isotonic saline (IS: 0.9%)
Number of subjects: 16
Study: 16004669

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 1085
Study: 12361426

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 712

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 712
Study: 10731301

Group type: EXPERIMENTAL
Intervention: Bathing in a sulphur pool
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bathing in the Dead Sea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of sulphur pool and bathing in the Dead Sea
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no balneotherapy)
Number of subjects: 40
Study: 8550130

Group type: EXPERIMENTAL
Intervention: Nitroxazepine (25 mg PO, HS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1960313

Group type: EXPERIMENTAL
Intervention: Intravenous ribose (3.3 mg/kg per min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 15
Study: 6173512

Group type: EXPERIMENTAL
Intervention: Individual treatment (traditional, stimulus-response type treatment of specific language deficits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group therapy (designed to improve communication through group interaction and discussion, no direct treatment of specific language deficits)
Number of subjects: 0
Study: 31662370

Group type: EXPERIMENTAL
Intervention: PBMT/sMF before training sessions + PBMT/sMF during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBMT/sMF before training sessions + placebo during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo before training sessions + PBMT/sMF during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo before training sessions + placebo during detraining
Number of subjects: 0
Study: 28803834

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 25140032

Group type: EXPERIMENTAL
Intervention: Intervention group (group 1) with aerobic exercise program based on verbal and written guidelines
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 34
Study: 23651130

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 12 weeks at 30% of maximal inspiratory pressure (PImax)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG) following the same protocol without inspiratory load
Number of subjects: 31
Study: 21717887

Group type: EXPERIMENTAL
Intervention: Noise blocked group (earplugs inserted into both ears)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (earplugs not inserted)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 19439458

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet (LC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Isocaloric low-fat diet (LF)
Number of subjects: 118
Study: 17094121

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (regular coffee)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 15678736

Group type: EXPERIMENTAL
Intervention: Propofol (30 mg kg(‐1)h(‐1)) + Fentanyl (2 microg kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (30 mg kg(‐1)h(‐1)) + Normal Saline
Number of subjects: 40
Study: 12612777

Group type: EXPERIMENTAL
Intervention: Dentifrice with 550 ppm F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice with 275 ppm F
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest toothpaste (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice with 1,100 ppm F
Number of subjects: 0
Study: 9845405

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (effervescent)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (tablet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (effervescent)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (tablet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (tablet) vs Cimetidine 200 mg (tablet)
Number of subjects: 20
Study: 8601521

Group type: EXPERIMENTAL
Intervention: Moderate to marked MEP in tubes accompanying ovarian LMP tumors
Number of subjects: 191

Group type: COMPARATOR
Intervention: Normal tubes obtained for sterilization
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: MEP presence with ovarian LMP tumors
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: MEP presence with benign ovarian lesions, invasive gynecologic cancers, uterine leiomyomas, or tubal inflammatory lesions and ectopic pregnancies
Number of subjects: 191
Study: 2569435

Group type: EXPERIMENTAL
Intervention: Lactulose/breath hydrogen method
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sulphasalazine/sulphapyridine method
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Coadministration of lactulose and sulphazalazine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sulphasalazine at 1.5 g and 3.0 g
Number of subjects: 9
Study: 134249

Group type: EXPERIMENTAL
Intervention: Volon A40 (one ampoule injected intrathecally and peridurally)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard surgical procedure without Volon A40
Number of subjects: 160
Study: 31787550

Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Number of subjects: 738

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 738
Study: 31240322

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 2567
Study: 28243685

Group type: EXPERIMENTAL
Intervention: Single dose of 10 mg dimemorfan phosphate tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg dimemorfan phosphate tablets under fed conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg dimemorfan phosphate tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple-dosing of 20 mg dimemorfan phosphate tablets 3 times per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg dimemorfan phosphate tablets under fasting conditions
Number of subjects: 24
Study: 25512675

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 2 weeks at weeks 0-4; CZP 200 mg every 2 weeks at weeks 6-16
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo→CZP (placebo at weeks 0-2; CZP loading dose at weeks 2-6; CZP 200 mg every 2 weeks at weeks 8-16)
Number of subjects: 41
Study: 24259595

Group type: EXPERIMENTAL
Intervention: Medication Monitoring and Optimization (MeMO) program
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Usual care (historical reference group)
Number of subjects: 1002
Study: 21144679

Group type: COMPARATOR
Intervention: Term infants with perinatal intracerebral hemorrhage (ICH)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Term infants with perinatal asphyxia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Preterm infants with ICH
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 54
Study: 18053580

Group type: EXPERIMENTAL
Intervention: Light room therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study: 16203676

Group type: EXPERIMENTAL
Intervention: Bottle nipple with physical characteristics enhancing sucking skills
Number of subjects: 10
Study: 12484105

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT) plus relaxation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study: 9583664

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 28
Study: 8593994

Group type: EXPERIMENTAL
Intervention: Upright cycling without venous occlusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Upright cycling with venous occlusion (bilateral thigh cuffs inflated to 100 mmHg)
Number of subjects: 10
Study: 2576667

Group type: COMPARATOR
Intervention: Atenolol, 50 mg/day (Control)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Indenolol, 60 mg/day
Number of subjects: 143
Study: 1269217

Group type: COMPARATOR
Intervention: 0 mg dextroamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg dextroamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg dextroamphetamine
Number of subjects: 12
Study: 29309746

Group type: EXPERIMENTAL
Intervention: Meditation (10-min duration)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Brisk walking (10-min duration)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Active stretching (control group, 10-min duration)
Number of subjects: 63
Study: 27278101

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention delivered by mental health workers
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Generic stop‐smoking services
Number of subjects: 13
Study: 24673076

Group type: EXPERIMENTAL
Intervention: Encephalopathy therapeutic tongue acupoint apparatus (ETTAA) combined with conventional training (behavior training and sensory integration training) for 2 months, apparatus switched on for 20 min, 3 times a day.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional training (behavior training and sensory integration training) for 2 months.
Number of subjects: 84
Study: 20528781

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.04% for 3 min)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with free conjunctival autograft (sutured using 7-0 Vicryl)
Number of subjects: 115
Study: 19794135

Group type: EXPERIMENTAL
Intervention: Once-daily atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18793579

Group type: COMPARATOR
Intervention: Quantia 200 (generic quetiapine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Seroquel (innovator product)
Number of subjects: 24
Study: 15960405

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg x kg(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study: 12939113

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inotropes (Milrinone and Dobutamine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9849290

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shao Shang acupoints
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for laryngospasm
Number of subjects: 76
Study: 7861798

Group type: EXPERIMENTAL
Intervention: Adjusted quantity-frequency method with questions on occasions with heavy drinking
Number of subjects: 930
Study: 2511023

Group type: COMPARATOR
Intervention: NPH insulin (Group A, n = 11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: human proinsulin (Group B, n = 12)
Number of subjects: 23
Study: 1233383

Group type: EXPERIMENTAL
Intervention: Chlorpromazine-imipramine combination
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thio-thixene placebo
Number of subjects: 24